GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (OTCPK:IUGNF) » Definitions » EV-to-EBITDA

IUGNF (Imugene) EV-to-EBITDA : -1.44 (As of Dec. 12, 2024)


View and export this data going back to . Start your Free Trial

What is Imugene EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Imugene's enterprise value is $139.43 Mil. Imugene's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-97.11 Mil. Therefore, Imugene's EV-to-EBITDA for today is -1.44.

The historical rank and industry rank for Imugene's EV-to-EBITDA or its related term are showing as below:

IUGNF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -84.92   Med: -1.89   Max: -0.43
Current: -1.44

During the past 13 years, the highest EV-to-EBITDA of Imugene was -0.43. The lowest was -84.92. And the median was -1.89.

IUGNF's EV-to-EBITDA is ranked worse than
100% of 445 companies
in the Biotechnology industry
Industry Median: 9.7 vs IUGNF: -1.44

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-12), Imugene's stock price is $0.0299. Imugene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.014. Therefore, Imugene's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Imugene EV-to-EBITDA Historical Data

The historical data trend for Imugene's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene EV-to-EBITDA Chart

Imugene Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.28 -94.99 -25.47 -8.45 -2.28

Imugene Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.47 - -8.45 - -2.28

Competitive Comparison of Imugene's EV-to-EBITDA

For the Biotechnology subindustry, Imugene's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imugene's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Imugene's EV-to-EBITDA falls into.



Imugene EV-to-EBITDA Calculation

Imugene's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=139.430/-97.111
=-1.44

Imugene's current Enterprise Value is $139.43 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imugene's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-97.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Imugene  (OTCPK:IUGNF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Imugene's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0299/-0.014
=At Loss

Imugene's share price for today is $0.0299.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Imugene's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.014.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Imugene EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Imugene's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Imugene Business Description

Traded in Other Exchanges
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.